((4S,5R)-2-(4-(tert-Butyl)-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethyl-4,5-dihydro-1H-imidazol-1-yl)(4-(3-(methylsulfonyl)p ropyl)piperazin-1-yl)methanone
CAS: 939981-39-2
Ref. 3D-PMB98139
1mg | Discontinued | ||
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued |
Product Information
(4S,5R)-2-(4-(tert-Butyl)-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethyl-4,5-dihydro-1H-imidazol-1-yl)(4-(3-(methylsulfonyl)prop yl)piperazin-1-yl)methanone (TPI) is a synthetic compound that has been shown to have potent cytotoxicity against cancer cells in vitro. TPI targets protein-protein interactions and is currently being investigated for its potential as a cancer therapy. It has also been shown to be effective in the treatment of skin cancers in mouse models. TPI has not yet been tested on humans and there are no clinical data available.